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ABSTRACT
Management of castration-resistant prostate cancer (CRPC) is challenging 
due to lack of efficacious therapy. Luteinizing hormone-releasing hormone (LHRH) 
analogs appear to act directly on cells based on the LHRH receptors on human 
prostate adenocarcinoma cells. We explored anticancer activity of a cytotoxic analog 
of LHRH, AEZS-108, consisting of LHRH agonist linked to doxorubicin. Nude mice 
bearing DU-145 tumors were used to compare antitumor effects of AEZS-108 with 
its individual constituents or their unconjugated combination. The tumor growth 
inhibition of conjugate was greatest among treatment groups (90.5% inhibition vs. 
41% by [D-Lys(6)]LHRH+DOX). The presence of LHRH receptors on DU-145 cells 
was confirmed by immunocytochemistry. In vitro, AEZS-108 significantly inhibited 
cell proliferation (61.2% inhibition) and elevated apoptosis rates (by 46%). By the 
detection of the inherent doxorubicin fluorescence, unconjugated doxorubicin was 
seen in the nucleus; the conjugate was perinuclear and at cell membrane. Autophagy, 
visualized by GFP-tagged p62 reporter, was increased by AEZS-108 (7.9-fold vs. 5.3-
fold by DOX+[D-Lys(6)]LHRH. AEZS-108 more effectively increased reactive oxygen 
species (ROS, 2-fold vs. 1.4-fold by DOX+[D-Lys(6)]LHRH) and levels of the apoptotic 
regulator p21 in vivo and in vitro. We demonstrate robust inhibitory effects of the 
targeted cytotoxic LHRH analog, AEZS-108, on LHRHR positive castration-resistant 
prostate cancer cells.
INTRODUCTION
In 2014, prostate cancer is expected to account 
for 27% of newly detected cancers and 10% of cancer-
related deaths in men in the US [1]. Standard therapy 
of metastatic prostate cancer is androgen deprivation 
therapy (ADT) currently achieved by surgical orchiectomy 
or by treatment with LHRH agonist or antagonist 
[2-4]. Continuous administration of LHRH analogs 
downregulates pituitary LHRH receptors thus leading to 
the suppression of gonadotropin (luteinizing hormone and 
follicle-stimulating hormone) release and a consequent 
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drop in production of gonadal androgens [2, 5]. However, 
the attenuation of this pituitary-gonadal axis is preceded 
by an initial surge of LH that, in some cases, is responsible 
for a serious side effect termed “flare reaction” [6, 7]. To 
avoid side effects, antagonistic analogs of LHRH, that 
completely lack LH-releasing activity, have also been 
developed and approved for the management of advanced 
androgen-dependent prostate cancer [8-10]. 
Despite the initial success of ADT on suppressing 
tumor growth, prostate cancer cells may progress to 
androgen independence (also referred to as castration 
resistance) which situation narrows the number of effective 
treatments. Patients with castrate resistant prostate cancer 
(CRPC) have a poor prognosis with an expected survival 
of less than 19 months [11]. There are a few treatment 
options of chemotherapy for advanced CRPC but none of 
them are markedly effective [12].
LHRH and its receptor (LHRH-R) are not limited to 
the hypothalamic-pituitary axis [13]. In the periphery, the 
LHRH system regulates gonadal functions and appears to 
serve as a growth factor of benign conditions [14-17] and 
various cancers including breast, lung, ovary, endometrial, 
kidney, bladder, colon, pancreas and prostate [18-25]. 
A specific, medium to high-affinity binding site for an 
LHRH agonist was found in 86% of prostate cancers [23]. 
In addition, expression of LHRH receptor by prostate 
cancer cells is preserved even after a prolonged exposure 
to LHRH agonist; LHRH receptors also appear in lymph 
node metastases [26]. These findings imply that the LHRH 
receptor is a suitable object for the design of an approach 
based on targeted chemotherapy [27]. Accordingly, 
various cytotoxic conjugates of LHRH have been 
produced of which AEZS-108 (previously known as AN-
152) has been chosen for clinical development [28-30]. 
This compound consists of an agonistic analog of LHRH, 
[D-Lys6]-LHRH, linked to the cytotoxic anthracycline, 
doxorubicin. In this hybrid, doxorubicin remains active 
and becomes specifically targeted to cells that possess 
cell membrane LHRH receptors, thereby making it less 
toxic to other cells [31, 32]. The unconjugated doxorubicin 
diffuses through the cell membranes and accumulates 
in the nucleus where it intercalates into the DNA. By 
targeting topoisomerase-II, it triggers enzyme-mediated 
DNA damage [33, 34]. Furthermore, doxorubicin elevates 
the concentration of reactive oxygen species (ROS) and 
triggers the activation of the ceramide signaling pathway – 
both processes being antiproliferative and toxic to the cells 
[35-40]. In contrast, AEZS-108 is taken up by the cells 
by receptor internalization and the doxorubicin moiety is 
subsequently cleaved off in the cell [41, 42]. This suggests 
a delayed doxorubicin-induced cytotoxicity in cells that 
are otherwise sensitive to doxorubicin. However, previous 
findings showed that AEZS-108 is more effective in 
inducing apoptosis in ovarian and endometrial carcinoma 
cell lines in vitro than doxorubicin alone [43].
In the current study, we investigated the antitumor 
activity of AEZS-108 in the CRPC DU-145 tumors in vivo 
and in vitro. Additionally, we explored the mechanism of 
its action in vitro, by studying its intracellular dynamics, 
measuring its effect on apoptosis and autophagy, and 
detecting its potential to activate doxorubicin-mediated 
intra- and extranuclear signals. Our findings indicate 
that AEZS-108 is a highly promising compound for the 
treatment of CRPC not only due to its targeted nature 
but also because of the potential of the different uptake 
mechanism to strengthen the extranuclear toxic activity 
of doxorubicin.
RESULTS
Inhibition of tumor growth in nude mice by 
AEZS-108
Nude mice bearing xenografted tumors of castration-
resistant prostate DU-145 cells were randomized into 5 
treatment groups: control (vehicle), AEZS-108 (6.9 µmol/
kg), DOX (6.9 µmol/kg), [D-Lys(6)]LHRH (6.9 µmol/
kg), and the combination of unconjugated DOX and 
[D-Lys(6)]LHRH (Fig.1A). Tumor growth was already 
significantly decreased compared to control at week 
1 (71% inhibition vs control, p<0.01); this remained 
significant throughout the 8 weeks of treatment. The 
cytotoxic LHRH analog completely blocked tumor 
growth at the end of the treatment resulting in a 90.5 % 
inhibition compared to control and was also significantly 
better than [D-Lys(6)]LHRH (p<0.01) and DOX alone 
(p<0.05). The unconjugated DOX, [D-Lys(6)]LHRH 
or their combination were unsuccessful in inducing 
significant reduction in tumor growth. As revealed by 
Western blot analysis of tumors removed at the end of the 
treatment, AEZS-108 was also highly potent in elevating 
protein levels of p21, a key activator of tumor suppressor 
pathways (Fig.1B). 
Immunocytochemical localization of LHRH 
receptors in DU-145 cells
Expression and cellular distribution of LHRH 
receptors in castration-resistant DU-145 cells was revealed 
by immunocytochemistry (Fig.2). We found that LHRH 
receptors are present on the cell membrane and therefore 
they can act to facilitate the selective uptake of AEZS-108 
in these cells. 
AEZS-108 inhibits proliferation and increases 
apoptotic cell death in DU-145 cells
Cell density was measured after a two-day 
incubation with 100 nM or 250 nM doxorubicin (DOX), 
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[D-Lys(6)]LHRH) (LHRH), the combination of DOX 
and LHRH or AEZS-108, respectively, by the MTS 
assay. DOX and its combination with LHRH reduced 
the proliferation by 14.8% (p<0.01) and 11.3% (p<0.05) 
at 100 nM concentration, respectively, and 52% and 
42.8% at 250 nM concentration (p<0.001), respectively, 
compared to control. LHRH on its own had little effect 
on proliferation. The cytotoxic compound, AEZS-108 
on the other hand was the most efficacious in inhibiting 
proliferation, reducing it by 23.2 % and 61.2 % at 100 
nM and 250 nM (p<0.001), respectively, compared to 
control. The increase in apoptotic cell death was measured 
after a 1-day incubation with 1 µM DOX, [D-Lys(6)]
LHRH), their combination or AEZS-108, respectively, by 
measuring the binding of FITC-conjugated Annexin-V. 
The elevation in apoptotic cell death was only significant 
when AEZS-108 was used (46% elevation, p<0.05). 
Figure 1: Treatment with cytotoxic luteinizing 
hormone-releasing hormone (LHRH) analog, AEZS-
108, significantly inhibited the growth of DU-145 
castration-resistant prostate cancer xenografted into 
nude mice and upregulated the protein levels of p21 
WAF1/Cip1. A: Mice were given vehicle (control), 6.9 µmol/
kg AEZS-108, 6.9 µmol/kg doxorubicin (DOX), 6.9 µmol/kg 
[D-Lys(6)]LHRH) or the combination of unconjugated DOX 
and [D-Lys(6)]LHRH in weekly i.v. injections. Tumor volumes 
were assessed each week and percent changes in tumor volumes 
are shown (± SEM) relative to tumor volumes at the initiation 
of treatment. Statistical analysis was performed by one-way 
ANOVA, followed by Holm-Sidak test.*: p < 0.05, **: p < 0.01, 
***: p < 0.001 vs. control. B: Western blot showing protein 
levels of p21 WAF1/Cip1 in tumors collected at the end of the 
experiment. β-actin was used as loading control. Fold-changes 
in protein levels are shown relative to control and normalized 
to β-actin levels. Membrane shown is representative of two 
experiments. 
Figure 2: DU-145 cells express receptors of LHRH 
on the cell membrane. LHRH receptors were labelled by 
using immunocytochemistry (green), the actin cytoskeleton was 
visualized by TRITC-conjugated phalloidin (red) and nuclei 
were stained with DAPI (blue). Scale bar corresponds to 100 
µm. 
Figure 3: AEZS-108 suppresses the proliferation (A) and induces apoptosis (B) in DU-145 castration-resistant prostate 
cancer cells in vitro. A: Cells were split into a 96-well plate at 5000 cells/well density, starved for one day in serum free medium and 
treated with 100 nM or 250 nM of doxorubicin (DOX), [D-Lys(6)]LHRH (LHRH), the combination of DOX and LHRH or AEZS-108 in 
0.5 % serum-containing growth medium. B: The density of apoptotic cells were measured by detecting the accumulation of annexin-V after 
a 1-day treatment with 1 µM doxorubicin (DOX), [D-Lys(6)]LHRH (LHRH), the combination of DOX and LHRH or AEZS-108 diluted in 
serum-free medium. Statistical analysis was performed by one-way ANOVA, followed by Holm-Sidak test.*: p < 0.05, **: p < 0.01, ***: 
p < 0.001 vs. control.
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The intracellular distribution of AEZS-108 and 
the unconjugated doxorubicin are dissimilar 
The intrinsic fluorescence of doxorubicin was 
detected in DU-145 cells after they were treated with 
either 5 µM unconjugated doxorubicin or AEZS-108 
(Fig.4.). After 20 or 60 minutes of incubation, the 
unconjugated doxorubicin was predominantly localized in 
the nucleus. In contrast, the cytotoxic LHRH compound 
showed a gradual cellular uptake, accumulating at the 
cell membrane and in the perinuclear space and showing 
a limited presence in the nucleus. This indicates that the 
compound spends extended time outside the nucleus 
before the subsequently cleaved doxorubicin reaches the 
nuclear DNA. 
Short-term treatment with AEZS-108 and 
doxorubicin 
To assess the difference in DNA damage caused by 
a short term incubation with the unconjugated doxorubicin 
or AEZS-108, we used immunocytochemistry with an 
antibody recognizing the phosphorylated form of the 
histone variant, γ-H2AX (Fig.5). After 60 minutes of 
incubation, the unconjugated form of doxorubicin was 
noticeably more efficient than AEZS-108 in increasing 
the phosphorylation of γ-H2AX. This finding provides 
evidence for the delayed transport of doxorubicin when it 
is in conjugated form in the cytotoxic compound, AEZS-
108. 
The cytotoxic LHRH analog, AEZS-108, increases 
the rate of autophagy and the generation of 
reactive oxygen species (ROS)
The induction of autophagy was measured after 1 
day of incubation with 1µM DOX, [D-Lys(6)]LHRH, 
the combination of DOX and LHRH or AEZS-108, 
respectively, by using the GFP-tagged p62 reporter 
construct (Fig.6a). Doxorubicin, [D-Lys(6)]LHRH and 
their unconjugated combination increased the rate of 
autophagy by 5, 3.5 and 5.3-fold, respectively, although 
the effect of [D-Lys(6)]LHRH alone was not significant 
(p<0.01 for DOX and DOX + [D-Lys(6)]LHRH. More 
intriguingly, AEZS-108 increased the rate of autophagy by 
8-fold (p<0.001). The effect of the same treatments on the 
generation of ROS was measured by a 3′-(p-aminophenyl) 
fluorescein. Only the cytotoxic compound AEZS-108 
increased the level of ROS significantly (2-fold increase, 
p<0.01).
AEZS-108 and doxorubicin regulate the protein 
level of p21 and the phosphorylation of γ-H2AX 
differently
Protein levels of p21 and the phosphorylation 
of γ-H2AX were measured after 1 day of incubation 
with 1µM DOX, [D-Lys(6)]LHRH, their unconjugated 
combination or AEZS-108, respectively, in DU-145 cells. 
Interestingly, p21 level was elevated by AEZS-108 to a 
much higher extent than was achieved by the incubation 
with the unconjugated DOX and [D-Lys(6)]LHRH 
combination. In contrast, the phosphorylation of γ-H2AX 
was similar in the DOX, DOX+[D-Lys(6)]LHRH and 
Figure 4: The intracellular distribution of AEZS-108 and doxorubicin are different after a short incubation in DU-145 
castration-resistant cells. Cells were incubated with 5 µM unconjugated doxorubicin or AEZS-108 for 20 or 60 minutes in serum-free 
medium. Nuclei were labelled with Hoechst dye (blue). Cells were fixed in 4% paraformaldehyde, mounted and images were acquired 
immediately by using the inherent fluorescence of doxorubicin. Scale bar corresponds to 10 µm. 
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AEZS-108 treated cells, indicating that the doxorubicin 
moiety subsequently cleaved from AEZS-108 also reached 
and caused damage in the nucleus. Histone H3 and β-actin 
were used as loading controls.
DISCUSSION
Cytotoxic conjugates of peptide analogs assist 
the tumor-specific targeting of cytotoxic drugs thereby 
increasing efficacy and limiting toxicity to the non-
tumoral tissue [27, 44-50]. LHRH was selected for the 
development cytotoxic conjugates based on the presence 
of its receptor in various tumoral tissues including 
ovarian, endometrial, colorectal, pancreatic, bladder and 
prostate cancer as well as in glioblastoma [13, 28-30, 51-
53]. More than 80% of resected human prostate cancers 
express LHRH receptors suggesting that patients with 
prostatic malignancies would benefit from therapy with 
the cytotoxic LHRH analog, AEZS-108 [23]. 
In an earlier study, AEZS-108 suppressed the 
growth of the human androgen sensitive MDA-PCa-2b 
Figure 6: The cytotoxic LHRH analog, AEZS-108, induces autophagy (A) and increases the level of intracellular ROS 
(B) in the DU-145 castration-resistant prostate cancer cells. Cells were incubated with 1 µM doxorubicin (DOX), [D-Lys(6)]
LHRH) (LHRH), the combination of DOX and LHRH or AEZS-108 for 24 hours in serum-free medium. The rate of autophagy was measured 
by labelling autophagosomes with the GFP-tagged p62 reporter transduced by baculovirus. ROS level was detected by APF fluorescent 
reagent. Fluorescent intensity was measured with a Victor3 plate reader. After measurement, cells were fixed in 4% paraformaldehyde and 
representative images were taken with a Nikon Eclipse Ti fluorescence microscope with a 20x objective. Statistical analysis was performed 
by one-way ANOVA, followed by Holm-Sidak test.*: p < 0.05, **: p < 0.01, ***: p < 0.001 vs. control.
Figure 7: AEZS-108 elevates the protein level of p21 
WAF1/Cip1 but its effect on the phosphorylation 
of γ-H2AX is comparable to that of unconjugated 
doxorubicin. Cells were incubated with 1 µM doxorubicin 
(DOX), [D-Lys(6)]LHRH) (LHRH), the combination of DOX 
and LHRH or AEZS-108 for 24 hours in serum-free medium 
and then were lysed and were subjected to Western blot analysis. 
A Histone H3 and β-actin were used as loading controls. Fold-
changes in p21 protein levels are shown relative to control and 
normalized to β-actin levels. Membrane shown is representative 
of two experiments.
Figure 5: The phosphorylation of the DNA 
breakdown marker, γ-H2AX, is markedly stimulated 
by doxorubicin but less affected by AEZS-108 in 
short-term experiments. Cells were incubated with 5 µM 
unconjugated doxorubicin or AEZS-108 for 60 minutes in serum-
free medium. Cells were then fixed in 4% paraformaldehyde 
and the phosphorylated γ-H2AX was labelled by using 
immunocytochemistry (green). Nuclei were labelled with DAPI 
(blue). Scale bar corresponds to 100 µm.
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and LNCaP cells as well as increased the rate of apoptosis 
in the castration-resistant bone metastasis model of C4-2 
prostate cancer cells [29]. Our aim here was to further 
elucidate the antitumor effects of AEZS-108 in castration-
resistant prostate cancer, a tumor that otherwise lacks 
effective treatment strategies. We selected an established 
cell line, DU-145, that is derived from a brain metastasis 
and manifests an epithelial nature [54], to compare the 
inhibitory activity of AEZS-108 with its unconjugated 
constituents, doxorubicin and [D-Lys(6)]LHRH. We 
found that the effect of AEZS-108 was much greater than 
that of the doxorubicin alone, or its combination with the 
unconjugated LHRH in completely blocking and reversing 
tumor growth. This high efficacy of the cytotoxic analog 
AEZS-108 is likely due to its accumulation in LHRH 
receptor positive DU-145 cells, since the combination of 
unconjugated DOX and [D-Lys(6)]LHRH was much less 
effective in suppressing tumor growth. 
In previous studies, AEZS-108 was also more 
effective than equimolar doses of doxorubicin to inhibit 
the growth of experimental human breast, bladder, 
pancreatic, ovarian and endometrial cancers [13, 51, 53, 
55, 56]. These experimental reports led to the first clinical 
trials that were carried out starting in 2008 [57]. A phase-I 
dose escalation study was completed in women with 
LHRH receptor positive ovarian, endometrial and breast 
cancer [32] and was followed by two phase II studies in 
patients with taxane-pretreated platinum-resistant ovarian 
cancer and with recurrent endometrial cancer [58, 59]. 
These studies showed no major toxicity in pituitary, heart 
or other organs [58, 59]. AEZS-108 was more efficient in 
patients with recurrent endometrial cancer: 5% of patients 
had a complete and 18% a partial remission; moreover, in 
44%, the disease was stable for at least 6 weeks [59]. A 
phase I study with taxane- and castration-resistant prostate 
cancer has also been finished rendering AEZS-108 safe for 
its use in phase II and III trials that are currently ongoing 
(unpublished). 
The increased antitumoral activity of the cytotoxic 
LHRH analog resides in its ability to home the doxorubicin 
moiety to LHRH receptor positive cancer cells where it 
undergoes binding and internalization [41, 42]. By using 
immunocytochemistry, we confirmed that the DU-145 
castration-resistant prostate cancer cells express LHRH 
receptors that are localized on the cell membrane rendering 
them susceptible to AEZS-108. In addition, we showed 
that there is a slow uptake of AEZS-108 in DU-145 cells, 
an effect, which may be responsible for its high efficacy in 
vitro. After a short, one-hour incubation with the cytotoxic 
analog, AEZS-108 was present at both the cell membrane 
and in the perinuclear area whereas doxorubicin diffused 
through the membrane to accumulate in the nucleus. 
Similar uptake dynamics of AEZS-108 have been shown 
in breast, ovarian and endometrial cancer cells by others, 
however, the authors have not compared the uptake of 
AEZS-108 to that of the unconjugated doxorubicin, and 
the significance of this extended extranuclear residence 
has not been discussed [41, 60]. 
Since the accumulation of doxorubicin derived 
from AEZS-108 in the nucleus is delayed, it is unlikely 
that the increased activity of the compound is due to 
its elevated effect on topoisomerase-II activity. This is 
supported by our finding that the phosphorylation of the 
DNA-breakdown marker, γH2AX, is lower after a short 
incubation with AEZS-108 than with the unconjugated 
doxorubicin. An alternative cytotoxic mechanism for 
doxorubicin is considered to be its capability to raise 
the levels of ROS which process occurs mainly in the 
cytoplasm and mitochondria [61-63]. Accordingly, 
doxorubicin has been shown to increase the level of 
hydrogen peroxide in PC3 prostate cancer cells [64]. Since 
AEZS-108 remains extranuclear for an extended time, it is 
expected to influence intracellular ROS levels to a greater 
extent than the unconjugated DOX. Indeed, we found that 
AEZS-108 elevated ROS levels more significantly than 
the unconjugated DOX. In addition, higher ROS levels 
may contribute to the increased apoptotic effect of AEZS-
108 seen in our experiment [65].
Bioactive sphingolipids such as sphingosine, 
sphingosine-1-phosphate and ceramide are important 
regulators of survival, cell proliferation and death 
[35]. Increased levels of ceramide affect the activity of 
diverse signaling molecules leading to cell cycle arrest, 
autophagy and apoptosis [36]. Recently, doxorubicin has 
been shown to promote the synthesis of ceramide [37-
39]. Accumulation of ceramide induced by doxorubicin 
stimulates the proteolytic activation of CREB3L1, a 
transcription factor responsible for the transcription of 
various genes that inhibits cell proliferation, including 
p21 [38, 40]. The extended presence of AEZS-108 on 
cell membranes may facilitate the synthesis of ceramide 
and it may thereby produce a greater effect on this 
pathway than the unconjugated doxorubicin which simply 
diffuses across membranes [33, 34]. This idea seems to 
be supported by the increased rate of autophagy and the 
elevated levels of p21 in response to AEZS-108 in our 
experiments, both processes being regulated partly by the 
ceramide pathway [36]. However, further investigation is 
required to better understand the role of this pathway in 
cytotoxicity induced by AEZS-108. 
In conclusion, our results indicate that patients 
with castration-resistant prostate cancer may benefit 
from chemotherapy based on the targeted cytotoxic 
LHRH analog, AEZS-108. The peptide-conjugated form 
of doxorubicin allows a slower intracellular uptake of 
this drug that leads to increased effects on extranuclear 
targets, such as the generation of ROS and the activation 
of the ceramide pathway. Our findings provide a better 
understanding of the mechanism of action of cytotoxic 
peptide analogs and substantiate their use in clinical 
practice.
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METHODS
Cytotoxic compounds
LHRH agonist [D-Lys6]LHRH (pyroGlu-His-Trp-
Ser-Tyr-D-Lys-Arg-Pro-Gly-NH2) was synthesized in 
our laboratory by solid-phase methods as described [66]. 
DOX.HCl salt was purchased from Chemex Export-Import 
GmbH (Vienna, Austria). Cytotoxic LHRH conjugate 
AN-152 was first synthesized in our laboratory [27, 28]. 
AEZS-108 was made by AEterna/Zentaris (Frankfurt 
am Main, Germany). The compounds were dissolved in 
0.01 M aqueous acetic acid and diluted with 5.5% (w/v) 
aqueous D-mannitol.
Cell culture
The DU-145 castration-resistant prostate cancer 
cell line was obtained from the American Type 
Culture Collection (ATCC; Manassas, VA) and was 
maintained in culture using Eagle`s Minimum Essential 
Medium (EMEM; ATCC) supplemented with 10% 
FBS and antibiotics (100 U/mL penicillin, 100 μg/mL 
streptomycin). Cells were grown at 37 °C in a humidified 
95% air/5% CO2 atmosphere.
Animals and in vivo xenograft models of DU-145 
tumors
Male athymic nude mice (Ncr nu/nu) were 
obtained from the NCI (Frederick Cancer Research and 
Development Center, Frederick, MD), and maintained 
under pathogen-limited conditions. Four donor animals 
were injected subcutaneously with 107 DU-145 cells. The 
resulting tumors were removed aseptically and minced 
into 3 mm3 pieces for transplantation into both flanks of 
animals that was performed using trocar needles. When 
tumors reached an average volume of 65 mm3, mice 
were randomized into five groups with nearly equal 
average tumor sizes. Mice received weekly intravenous 
injections of 6.9 µmol/kg doxorubicin, [D-Lys(6)]LHRH, 
their combination, AEZS-108 or vehicle. Tumor size 
was measured with a microcaliper at each week. Tumor 
volume [67] and tumor inhibition [68, 69] were calculated 
as previously described. At the end of the experiment, 
mice were sacrificed by cervical dislocation and tumors 
were removed and snap frozen. Specimens were stored at 
-80oC for further investigation.
Proliferation assay
Cells were seeded in 96-well plates at 2,500 cells/ 
well density in complete growth medium and were 
incubated for 24 hrs. After 24 hrs, culture medium was 
replaced by serum-free medium for another 24 hrs. This 
was followed by the addition of 100 nM or 250 nM of 
unconjugated doxorubicin, [D-Lys(6)]LHRH), their 
combination, or AEZS-108 in medium containing 0.5 
% heat-inactivated serum; the cells were then incubated 
for a further 48 h. At the end of the treatment the relative 
number of viable cells was measured using MTS assay 
(CellTiter 96 AQueous Assay; Promega, Madison, WI) 
following manufacturer’s instructions. Absorbance was 
measured at 490 nm in a Victor 3 Multilabel Counter 
(Perkin-Elmer, Waltham, MD). Experiments were 
performed in hexaplicate. Values were expressed relative 
to the control.
Apoptosis assay
Cells were seeded into a 24-well plate at 100,000 
cells/well density in complete growth medium and were 
incubated for 24 hrs. Afterwards, medium was replaced 
with serum-free medium containing 1 µM unconjugated 
doxorubicin, [D-Lys(6)]LHRH), their combination, 
or AEZS-108. Twenty-four hours later, cells were 
trypsinized, collected into microcentrifuge tubes and the 
rate of apoptosis was measured by the Multi-Parameter 
Apoptosis Assay Kit (Cayman Chemical Company, Ann 
Arbor, MI) according to the manufacturer`s instructions. 
Experiments were performed in triplicate. Values were 
expressed relative to the control.
Detection of ROS
Cells were seeded at 20,000 cells/well density 
into a 96-well plate in complete growth medium. One 
µM unconjugated doxorubicin, [D-Lys(6)]LHRH), their 
combination, or AEZS-108 was added to the cells in 
serum-free medium for 24 hrs. The ROS sensor reagent, 
aminophenyl fluorescein (Life technologies, Grand Island, 
NY) was added to the cells at 5 µM concentration for 20 
minutes. Medium was replaced with serum- and phenol 
red-free medium and fluorescence was measured in a 
Victor 3 Multilabel Counter (at excitation and emission 
wavelengths of 485 nm and 535 nm, respectively). 
Experiments were performed in hexaplicate. Values were 
expressed relative to the control.
Measurement of density of autophagic vacuoles
Cells were seeded at 20,000 cells/well density 
into a 96-well plate in complete growth medium. The 
next day, cells were transduced by green fluorescent 
protein-tagged LC3B protein by using the baculovirus 
technique (Premo™ Autophagy Sensor, Life technologies) 
according to the manufacturer`s instructions. Medium 
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was replaced the next day with serum-free medium 
containing 1 µM unconjugated doxorubicin, [D-Lys(6)]
LHRH), their combination or AEZS-108. Fluorescence 
was detected in serum- and phenol red-free medium in a 
Victor 3 Multilabel Counter (at excitation and emission 
wavelengths of 485 nm and 535 nm, respectively). 
Experiments were performed in hexaplicate. Values were 
expressed relative to the control.
Immunocytochemistry and fluorescence 
microscopy
DU-145 cells were seeded onto multiwell 
chamberslides (Millipore, Billerica, MA) and were left to 
adhere overnight. For the drug-uptake studies, cells were 
incubated with 5 µM of the unconjugated doxorubicin 
or AEZS-108 for 20 or 60 minutes, respectively. The 
nucleus marker Hoechst 33342 dye (Life Technologies) 
was added 10 minutes before the end of the incubation. 
Cells were then washed 3 times with PBS, were fixed 
in 4% paraformaldehyde for 15 minutes, and mounted 
in Vectashield mounting medium (Vector Laboratories, 
Burlingame, CA). Fluorescence was detected by a Nikon 
Eclipse Ti fluorescence microscope (Nikon Instruments, 
Melville, NY).
For immunocytochemistry, cells were incubated 
with 5 µM the unconjugated doxorubicin or AEZS-108, 
respectively, for 60 minutes. Afterwards, cells were washed 
with PBS 3 times and fixed in 4% paraformaldehyde for 7 
minutes. Permeabilization was performed by a 10-minute 
incubation in PBS containing 0.2 % Triton-X and then 
cells were blocked with 2% goat serum in PBS for 30 min. 
A specific antibody against the phosphorylated (at Ser139) 
histone variant γ-H2AX (1:50 dilution, Cell Signalling 
Technology, Danvers, MA) or the human LHRH receptor 
(1:100 dilution, Abcam, Cambridge, MA) was diluted in 
PBS and added to the cells for one hour. Anti-rabbit or 
anti-goat secondary antibodies (Alexa Fluor 488; Jackson 
Immunoresearch, West Grove, PA) were also applied for 
1 h. Coverslips were mounted in Vectashield mounting 
medium containing DAPI for nuclear staining (Vector 
Laboratories). Images were acquired on a Nikon Eclipse 
Ti fluorescence microscope.
Western blot
Tumors and cells were homogenized and sonicated 
in RIPA buffer and debris was removed by centrifugation 
at 14,000 g for 15 minutes. Protein concentration was 
determined by BCA protein assay (Thermo Fisher 
Scientific, Waltham, MA). Western blot analyses were 
as extensively described [70]. Briefly, equal amount 
of proteins were mixed with Laemmli buffer (Bio-Rad 
Laboratories Inc., Hercules, CA) and were incubated 
at 98oC for 8 minutes on a heat block. Proteins were 
separated by 4-15% PAGE and were transferred onto 
PVDF membrane. Blocking was performed with Clear 
milk blocking buffer (Thermo Fisher Scientific) for half 
an hour. Primary antibodies p21, γ-H2AX, Histone H3 
(1:1000 dilution, Cell Signalling Technology) and β-actin 
(1:10,000 dilution, Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA) were added to the membranes for overnight 
incubation. Species-specific HRP-conjugated secondary 
antibodies (Thermo Fisher Scientific) were left on the 
membranes for 1.5 hrs and the signal was developed with 
ECL reagent (Thermo Fisher Scientific) and then imaged 
with a Bio-Rad Chemidoc System. Densitometry was 
performed using ImageJ software (NIH, Bethesda, MD).
Statistical analysis
Statistical analyses were performed using analysis 
of variance (ANOVA) followed by Holm-Sidak post hoc 
test calculated by Sigma Plot software (Systat Software 
Inc, Chicago, IL). Results are expressed as the means ± 
SEM. Differences with p<0.05, compared to the control, 
were considered statistically significant. 
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